ATE534393T1 - Zusammenstellungen zur energiesteigerung in vivo - Google Patents

Zusammenstellungen zur energiesteigerung in vivo

Info

Publication number
ATE534393T1
ATE534393T1 AT99928759T AT99928759T ATE534393T1 AT E534393 T1 ATE534393 T1 AT E534393T1 AT 99928759 T AT99928759 T AT 99928759T AT 99928759 T AT99928759 T AT 99928759T AT E534393 T1 ATE534393 T1 AT E534393T1
Authority
AT
Austria
Prior art keywords
compositions
reduced energy
pentose
vivo
sugars
Prior art date
Application number
AT99928759T
Other languages
German (de)
English (en)
Inventor
John St Cyr
Clarence Johnson
Original Assignee
Bioenergy Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioenergy Inc filed Critical Bioenergy Inc
Application granted granted Critical
Publication of ATE534393T1 publication Critical patent/ATE534393T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT99928759T 1998-06-19 1999-06-17 Zusammenstellungen zur energiesteigerung in vivo ATE534393T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9000198P 1998-06-19 1998-06-19
US09/290,789 US6159942A (en) 1998-06-19 1999-04-12 Compositions for increasing energy in vivo
PCT/US1999/013720 WO1999065476A2 (en) 1998-06-19 1999-06-17 COMPOSITIONS FOR INCREASING ENERGY $i(IN VIVO)

Publications (1)

Publication Number Publication Date
ATE534393T1 true ATE534393T1 (de) 2011-12-15

Family

ID=26781174

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99928759T ATE534393T1 (de) 1998-06-19 1999-06-17 Zusammenstellungen zur energiesteigerung in vivo

Country Status (10)

Country Link
US (1) US6159942A (https=)
EP (1) EP1087779B1 (https=)
JP (5) JP2002518321A (https=)
CN (1) CN1306431A (https=)
AT (1) ATE534393T1 (https=)
AU (1) AU4575299A (https=)
CA (1) CA2334415C (https=)
ES (1) ES2374260T3 (https=)
NZ (1) NZ508478A (https=)
WO (1) WO1999065476A2 (https=)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020119933A1 (en) * 2000-07-28 2002-08-29 Butler Terri L. Compositions and methods for improving cardiovascular function
US6511964B2 (en) 1999-09-24 2003-01-28 Bioenergy, Inc. Method for treating acute mountain sickness
US6159943A (en) * 1999-09-24 2000-12-12 Bioenergy, Inc. Use of ribose to prevent cramping and soreness in muscles
US6339716B1 (en) * 1999-09-24 2002-01-15 Bioenergy Inc. Method for determining viability of a myocardial segment
US6703370B1 (en) * 1999-10-27 2004-03-09 Bioenergy, Inc. Use of ribose to treat fibromyalgia
GB2353217B (en) * 1999-10-27 2001-07-18 Bioenergy Inc Use of ribose to treat fibromyalgia
AU1800801A (en) * 1999-11-17 2001-05-30 Eric H. Kuhrts Exercise and muscle enhancement formulations
DE10085291T1 (de) 1999-12-21 2003-05-08 Bioenergy Inc Zusammensetzungen für die Lagerung von Blutplättchen
CA2397707A1 (en) * 2000-01-07 2001-07-19 Susan S. Percival Compositions for enhancing the immune response
WO2001052831A1 (en) 2000-01-20 2001-07-26 Bioenergy Inc. Use of ribose supplementation for increasing muscle mass and decreasing body fat in humans
US6553254B1 (en) * 2000-04-07 2003-04-22 Keith E. Kenyon Combination of non-living-source physical energy and living-source chemical energy to maximize the salvage of ATP
US6835750B1 (en) 2000-05-01 2004-12-28 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
US6420342B1 (en) 2000-05-08 2002-07-16 N.V. Nutricia Nutritional preparation comprising ribose and medical use thereof
IT1317043B1 (it) * 2000-06-14 2003-05-26 Sigma Tau Healthscience Spa Integratore alimentare potenziante il metabolismo energeticomuscolare, comprendente una alcanoil l-carnitina e ribosio.
CN1299690C (zh) * 2000-07-28 2007-02-14 生物能量公司 用于提高心血管功能的组合物
US6855727B2 (en) * 2000-12-04 2005-02-15 Yaizu Suisankagaku Industry Co., Ltd. Muscular fatigue-controlling composition and method for providing muscular fatigue-controlling effect
EP1247525A1 (en) * 2001-04-02 2002-10-09 Bioenergy Inc. Use of a monosaccharide in the manufacture of a medicament against acute mountain sickness
US7629329B2 (en) * 2001-06-04 2009-12-08 Tsi Health Sciences, Inc. Method for increasing muscle mass and strength through administration of adenosine triphosphate
GB2381451A (en) * 2001-11-01 2003-05-07 New Technology Res Ltd Pharmaco-dietary preparation having nutrition-supplementing and nutrition-enhancing effect
DE10215007A1 (de) * 2002-04-05 2003-10-16 Degussa Bioactives Deutschland Verwendung von Kreatinpyruvat zur Steigerung der Ausdauer bei hochintensiven körperlichen Intervallbelastungen
US7547450B2 (en) * 2002-10-24 2009-06-16 Nestec Ltd. Senior feline food
US6838562B2 (en) * 2003-04-01 2005-01-04 Sal Abraham Process for preparing a creatine heterocyclic acid salt and method of use
US8759315B2 (en) * 2003-05-14 2014-06-24 Viacell, Llc Methods for rejuvenating
US7687468B2 (en) * 2003-05-14 2010-03-30 Viacell, LLC. Rejuvenation of stored blood
US20040229205A1 (en) * 2003-05-16 2004-11-18 Ericson Daniel G. Compositions for the storage of platelets
BRPI0506485A (pt) * 2004-01-14 2007-02-13 Bioenergy Inc método para reduzir o tempo de recuperação de um mamìfero submetido a uma anestesia geral, método para aumentar a recuperação de sepsia e uma composição adequada para administração intravenosa
JP4754484B2 (ja) * 2004-03-18 2011-08-24 田辺三菱製薬株式会社 うつ様症状改善剤
JP2005336176A (ja) * 2004-04-28 2005-12-08 Tanabe Seiyaku Co Ltd 肉体疲労改善剤
EP1786436B1 (en) * 2004-04-29 2012-11-14 RiboCor, Inc. Method for improving ventilatory efficiency
US20100099630A1 (en) * 2004-04-29 2010-04-22 Maccarter Dean J Method for improving ventilatory efficiency
US7968138B2 (en) * 2004-07-23 2011-06-28 Arnold Nerenberg Food sweetener
US20060029644A1 (en) * 2004-08-06 2006-02-09 Kenyon Keith E In vitro biochemical reactions with free anhydrous D-ribose
WO2007001883A2 (en) * 2005-06-20 2007-01-04 Accera, Inc. Method to reduce oxidative damage and improve mitochondrial efficiency
US7566463B2 (en) 2006-05-03 2009-07-28 C. B. Fleet Company Oral rehydration compositions
US20080146579A1 (en) * 2006-12-15 2008-06-19 N.V. Nutricia Treatment of patients with chronic pulmonary diseases and nutritional compositions therefore
CA2674717C (en) * 2007-01-23 2015-10-13 Bioenergy, Inc. Use of d-ribose to treat cardiac arrhythmias
US20080312169A1 (en) * 2007-03-20 2008-12-18 Clarence Albert Johnson Cosmetic use of D-ribose
US20090197819A1 (en) * 2007-03-20 2009-08-06 Clarence Albert Johnson Compositions for improving and repairing skin
CN101356971B (zh) * 2007-07-30 2012-11-07 石药集团中奇制药技术（石家庄）有限公司 一种用于抗疲劳耐缺氧的保健食品组合物
CA2853992C (en) 2007-07-31 2020-06-23 Cerecin Inc. Use of genomic testing and ketogenic compounds for treatment of reduced cognitive function
US20090061016A1 (en) * 2007-09-05 2009-03-05 Selzer Jonathan A Seawater Based Dietary Supplement Product for Energy and Electrolyte Replacement
US20090232750A1 (en) * 2008-03-13 2009-09-17 St Cyr John A Compositions for indoor tanning
EP2413942A1 (en) * 2008-04-02 2012-02-08 Bioenergy Inc. Use of ribose in first response to acute myocardial infarction
ES2422596T3 (es) 2008-05-16 2013-09-12 Robert V Kasubick Uso de ribosa en el tratamiento del síndrome de las piernas inquietas
AU2009266869B2 (en) 2008-07-03 2016-07-07 Cerecin Inc. Monoglyceride of acetoacetate and derivatives for the treatment of neurological disorders
AU2009283215B2 (en) * 2008-08-20 2014-12-04 Bioenergy, Inc. Use of D-ribose for fatigued subjects
IT1391588B1 (it) * 2008-10-15 2012-01-11 Giellepi Chemicals S P A Composizione sinergica per il recupero e la riduzione del danno ischemico lieve
US8255453B2 (en) 2009-09-14 2012-08-28 International Business Machines Corporation Public BOT management in private networks
US8765432B2 (en) 2009-12-18 2014-07-01 Oligasis, Llc Targeted drug phosphorylcholine polymer conjugates
JP5823985B2 (ja) 2010-02-16 2015-11-25 ビアセル，リミティド ライアビリティ カンパニー 赤血球を治療するためのアルギニン含有組成物および方法
US20110229871A1 (en) * 2010-02-16 2011-09-22 Ericson Daniel G Nucleoside-containing compositions and methods for treating red blood cells
CN102058045B (zh) * 2010-10-26 2012-09-19 开平牵牛生化制药有限公司 一种用于补充人体能量和恢复疲劳的饮品
JP6463361B2 (ja) 2013-09-08 2019-01-30 コディアック サイエンシーズ インコーポレイテッドＫｏｄｉａｋ Ｓｃｉｅｎｃｅｓ Ｉｎｃ． 第ｖｉｉｉ因子両性イオンポリマーコンジュゲート
CA2951567C (en) 2014-06-12 2023-10-31 Lonza, Inc. Method for decreasing skeletal muscle damage and/or oxidative stress in mammals
CA2966628C (en) * 2014-11-03 2023-08-29 Bioenergy Life Science, Inc. Use of d-ribose to enhance adaptation to physical stress
BR112018012410B1 (pt) 2015-12-18 2022-12-20 Lonza Consumer Health Inc Composição para o aumento da síntese de proteína e/ou força funcional musculares em mamíferos
EP4241838A3 (en) 2016-02-01 2023-12-20 Bioenergy Life Science, Inc. Use of ribose for treatment of subjects having congestive heart failure
CN108433106A (zh) * 2017-11-07 2018-08-24 付少才 一种耐缺氧活性果糖粉(液)组合物
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
WO2023135827A1 (ja) * 2022-01-13 2023-07-20 ＮｅＳＡ合同会社 神経変性疾患の進行遅延及び防御剤

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6049764A (ja) * 1983-08-29 1985-03-19 Ajinomoto Co Inc 食品組成物
JPS6094075A (ja) * 1983-10-31 1985-05-27 Ajinomoto Co Inc 果汁飲料組成物
US4719201A (en) * 1985-02-07 1988-01-12 Regents Of The University Of Minnesota Method for stimulating recovery from ischemia
US4605644A (en) * 1985-02-07 1986-08-12 Regents Of The University Of Minnesota Method for stimulating recovery from ischemia employing ribose and adenine
US4824660A (en) * 1985-06-06 1989-04-25 Paul S. Angello Method of determining the viability of tissue in an organism
JPS6232860A (ja) * 1985-08-06 1987-02-12 Riichiro Yamazaki 健康食品
US4920098A (en) * 1986-09-17 1990-04-24 Baxter International Inc. Nutritional support or therapy for individuals at risk or under treatment for atherosclerotic vascular, cardiovascular, and/or thrombotic diseases
JPH02212A (ja) * 1987-10-14 1990-01-05 Takeda Chem Ind Ltd 経口用水性製剤
AU2228888A (en) * 1987-10-14 1989-05-25 Takeda Chemical Industries Ltd. Aqueous pharmaceutical preparation for oral administration
US4871718A (en) * 1987-12-29 1989-10-03 Raymond A. Roncari Composition of matter for increasing intracellular ATP levels and physical performance levels and for increasing the rate of wound repair
US4981687A (en) * 1988-07-29 1991-01-01 University Of Florida Compositions and methods for achieving improved physiological response to exercise
US4968719A (en) * 1989-04-03 1990-11-06 Sigma Tau, Industrie Farmaceutiche Riunite Spa Method for treating vascular disease
US5114723A (en) * 1990-02-27 1992-05-19 University Of Texas System Board Of Regents Beverage compositions for human consumption
FR2668039B1 (fr) * 1990-10-18 1993-06-25 Pernod Ricard Boisson dietetique destinee a permettre de soutenir l'effort.
IT1247125B (it) * 1991-03-01 1994-12-12 Depha Team Srl Composizioni dietetiche o farmaceutiche per il ripristino del contenuto cellulare degli adenin nucleotidi nel muscolo scheletrico e cardiaco.
US5292538A (en) * 1992-07-22 1994-03-08 Metagenics, Inc. Improved sustained energy and anabolic composition and method of making
GB9215746D0 (en) * 1992-07-24 1992-09-09 Hultman Eric A method of increasing creatine supply depot
DE4228215A1 (de) * 1992-08-25 1994-03-03 Pliml Wolfgang Verwendung von Ribose zur Herstellung eines Arzneimittels zur Behandlung von Leistungsschwächen des Körpers, insbesondere von Organinsuffizienzen
US5852058A (en) * 1993-06-11 1998-12-22 The Board Of Trustees Of The Leland Stanford Junior University Intramural delivery of nitric oxide enhancer for inhibiting lesion formation after vascular injury
JPH07233070A (ja) * 1994-02-23 1995-09-05 Taisho Pharmaceut Co Ltd 疲労改善剤
JP3213666B2 (ja) * 1994-02-28 2001-10-02 治彦 末岡 クレアチン飲料の製造方法
AU1780395A (en) * 1994-05-02 1995-11-09 Omeara (Proprietary) Limited Amino acid, carnitine and magnesium supplementation
US5536751A (en) * 1994-05-09 1996-07-16 The United States Of America As Represented By The Secretary Of The Army Pharmaceutical alpha-keto carboxylic acid compositions method of making and use thereof
JPH07330584A (ja) * 1994-06-08 1995-12-19 Taisho Pharmaceut Co Ltd 疲労改善剤
GB9517443D0 (en) * 1994-12-17 1995-10-25 Univ Nottingham Increasing creatine and glycogen concentration in muscle
JP3595373B2 (ja) * 1995-02-20 2004-12-02 治彦 末岡 クレアチン飲料
US5707971A (en) * 1995-06-07 1998-01-13 Life Resuscitation Technologies, Inc. Modulation of glycolytic ATP production
US5709971A (en) 1995-06-20 1998-01-20 Eastman Kodak Company Dye imbibition printing blanks with antistatic layer
GB9611356D0 (en) * 1996-05-31 1996-08-07 Howard Alan N Improvements in or relating to compositions containing Creatine, and other ergogenic compounds
JP3563892B2 (ja) * 1996-10-08 2004-09-08 伊藤ハム株式会社 体力増強・疲労回復剤及びそれを用いた食品
DE19650755A1 (de) * 1996-12-06 1998-06-10 Wolfgang Dr Pliml Anwendung von Ribose zur Leistungssteigerung
GB9715340D0 (en) * 1997-07-22 1997-09-24 Cerestar Holding Bv Beverages for enhanced physical performance

Also Published As

Publication number Publication date
JP2010168394A (ja) 2010-08-05
JP2013237697A (ja) 2013-11-28
CN1306431A (zh) 2001-08-01
ES2374260T3 (es) 2012-02-15
WO1999065476A2 (en) 1999-12-23
JP2014043453A (ja) 2014-03-13
JP2016153421A (ja) 2016-08-25
AU4575299A (en) 2000-01-05
EP1087779B1 (en) 2011-11-23
CA2334415C (en) 2004-08-24
US6159942A (en) 2000-12-12
WO1999065476A3 (en) 2000-04-06
JP2002518321A (ja) 2002-06-25
CA2334415A1 (en) 1999-12-23
EP1087779A2 (en) 2001-04-04
NZ508478A (en) 2003-10-31

Similar Documents

Publication Publication Date Title
ATE534393T1 (de) Zusammenstellungen zur energiesteigerung in vivo
Shimomura et al. Less body fat accumulation in rats fed a safflower oil diet than in rats fed a beef tallow diet
US5391550A (en) Compositions of matter and methods for increasing intracellular ATP levels and physical performance levels and for increasing the rate of wound repair
Kim et al. Attenuation of bacterial lipopolysaccharide-induced hepatotoxicity by betaine or taurine in rats
Bondonno et al. Vegetable-derived bioactive nitrate and cardiovascular health
Jones Dietary nitrate supplementation and exercise performance
Patel The role of nutrition in the management of lower extremity wounds
ESSÉN‐GUSTAVSSON et al. Fibre types, enzyme activities and substrate utilisation in skeletal muscles of horses competing in endurance rides
Naderi et al. Co-ingestion of nutritional ergogenic aids and high-intensity exercise performance
Reed et al. Stimulation of respiration in brown fat cells by epinephrine, dibutyryl-3′, 5′-adenosine monophosphate, and m-chloro (carbonyl cyanide) phenylhydrazone
IL198137A0 (en) Ketogenic diet
BR0208375A (pt) Composições de baixa resposta glicêmica
JP2002518321A5 (https=)
Zafeiridis The effects of dietary nitrate (beetroot juice) supplementation on exercise performance: A review
Johnston et al. Ultrastructure and metabolism of skeletal muscle fibres in the tench: effects of long-term acclimation to hypoxia
US6013273A (en) Treatment of endotoxic shock
CN101132786A (zh) 胍基乙酸的盐、加成化合物和络合化合物
Wang et al. Effects of dietary supplementation of DL-2-hydroxy-4 (methylthio) butanoic acid on antioxidant capacity and its related gene expression in lung and liver of broilers exposed to low temperature
Fabiano et al. Creatine as a treatment for depression: A brain bioenergetics perspective
Jiménez et al. Changes in fatty acid profiles of red blood cell membranes mediated by dietary nucleotides in weanling rats
RAO et al. Biologic effects of chronic ethanol consumption related to a deficient intake of carbohydrates
Rao et al. Dietary carbohydrate stimulates alcohol diet ingestion, promotes growth and prevents fatty liver in rats
Alonso et al. Adenosine monophosphates and glycogenolysis in frog gastric mucosa
Mathew et al. Assessment of nutritional quality of fish
YOSHIMURA et al. Lipolytic action of serotonin in brown adipose tissue in vitro

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1087779

Country of ref document: EP